JNJ

Johnson & Johnson
CAPPED RATING

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson (JNJ) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.6 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
D+
Factor Score 1.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 43.4
EV / EBITDA 20.7
Rev Growth YoY 5.9%
Gross Margin 67.8%
Price Return 3M 9.4%
Price Return 12M 50.3%
Catalyst Signal +0.02
Market Cap $687.9B
TTM Revenue $99.3B
Price / Sales 6.9
ROE 20.0%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.6) D+ (1.6) B+ (3.8) B (3.5) D+ (1.6) C+ (2.6)
2026-11-09 C+ (2.6) D+ (1.6) B+ (3.8) B (3.5) D+ (1.6) C+ (2.6)
2026-11-07 C+ (2.6) D+ (1.6) B+ (3.8) B (3.4) D+ (1.6) C+ (2.6)
2026-11-06 C+ (2.6) D+ (1.6) B+ (3.8) B (3.4) D+ (1.6) C+ (2.6)
2026-11-03 C+ (2.6) D+ (1.6) B+ (3.8) B (3.4) D+ (1.6) C+ (2.6)
Page 1 of 11
…